Results 31 to 40 of about 5,144 (141)

Ixekizumab Type I Allergy in a Patient With Psoriasis

JEADV Clinical Practice
A 52‐year‐old Caucasian woman was referred for an allergy workup of suspected type I allergy to the interleukin (IL)‐17A inhibitor ixekizumab. Five months after ixekizumab initiation, she suddenly developed intense pruritus and three small wheals at the ...
Carina Borst, Constanze Jonak, Christine Bangert   +2 more
doaj   +1 more source

Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)

Journal of Dermatological Treatment, 2023
Purpose Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A approved for the treatment of moderate-to-severe plaque psoriasis.
Andrea Chiricozzi, Matteo Megna, Alessandro Giunta, Carlo Giovanni Carrera, Paolo Dapavo, Anna Balato, Piergiorgio Malagoli, Stella Mazzoccoli, Aurora Parodi, Silvia Sabatino, Carlotta Buzzoni, Chu-Han Huang, Alessandra Narcisi   +12 more
doaj   +1 more source

Nail Psoriasis in Pediatric Populations

JEADV Clinical Practice, EarlyView.
ABSTRACT Pediatric nail psoriasis is an under‐recognized yet clinically important manifestation of psoriasis with both diagnostic and prognostic implications. Nail involvement in children is associated with greater overall disease severity, poorer treatment outcomes, and is a predictor for the development of psoriatic arthritis.
Aditya K. Gupta, Elizabeth Teasell, Federico Quadrelli, Bianca Maria Piraccini   +3 more
wiley   +1 more source

Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial

Rheumatology and Therapy
Introduction The objective of this analysis is to evaluate the improvement in spinal pain with ixekizumab, placebo, and adalimumab based on objective measures of inflammation response in patients with ankylosing spondylitis (AS).
Kurt de Vlam, Walter P. Maksymowych, Gaia Gallo, Proton Rahman, Philip Mease, Venkatesh Krishnan, Conor J. McVeigh, Jeffrey Lisse, Danting Zhu, Rebecca J. Bolce, Philip G. Conaghan   +10 more
doaj   +1 more source

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada, Yoshiko Maeda, Miyuki Hasegawa, Motonobu Sakaguchi, Takamasa Hashimoto, Teruko Narusawa, Nobuyoshi Takabayashi, Tomoko Takahashi, Taisuke Kondo, Shingo Kuroda   +9 more
wiley   +1 more source

Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population

Biologics: Targets & Therapy, 2021
Julia Berman,1,2,* Victoria Furer,2,3,* Mark Berman,2,3 Ofer Isakov,1,2 Devy Zisman,4,5 Amir Haddad,4 Ori Elkayam2,3 1Department of Medicine ‘T’, Sourasky Medical Center, Tel Aviv, Israel; 2Sackler Faculty of Medicine, Tel Aviv University, Tel ...
Berman J, Furer V, Berman M, Isakov O, Zisman D, Haddad A, Elkayam O   +6 more
doaj  

Severe de novo Ulcerative Colitis following Ixekizumab Therapy

Case Reports in Gastroenterology, 2018
Ixekizumab is a selective monoclonal antibody targeting interleukin-17A, approved for the treatment of chronic plaque psoriasis. It has rarely been associated with inflammatory bowel disease (IBD) in randomized trials only.
Jobin Philipose, Moiz  Ahmed, Pretty S. Idiculla, Stephen M. Mulrooney, Vivek V. Gumaste   +4 more
doaj   +1 more source

Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials

Dermatology and Therapy, 2023
Introduction Limited data exist on skin cancer risk in patients with psoriasis using biologics. Here, we report treatment-emergent adverse events (TEAEs) of skin cancer in patients treated with ixekizumab from psoriasis clinical trials.
Saxon D. Smith, Alexandros Stratigos, Matthias Augustin, Jose Manuel Carrascosa, Susanne Grond, Elisabeth Riedl, Wen Xu, Himanshu Patel, Mark Lebwohl   +8 more
doaj   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source